Doctor of Osteopathy Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Leigh O'Malley

Internal Medicine Sylva, NC Doctor of Osteopathy

NPI 1992762447 CMS profile 44669

98 Doctors Dr, Ste 200, Sylva, NC 28779

Open in the dashboard

General payments

$6,021

383 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Leigh O'Malley of Sylva, NC is reported in the CMS Open Payments database as having received $6,021 across 383 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 91st percentile of Internal Medicine profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $467 24
2024 General $695 36
2023 General $1,417 76
2022 General $1,032 61
2021 General $227 14
2020 General $321 23
2019 General $1,862 149

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Leigh O'Malley
  • Internal Medicine median
  • Middle half of Internal Medicine
  • National median

In program year 2025, general payments to Leigh O'Malley were reported at $467. Among 52,115 Internal Medicine profiles paid that year, the median was $156 and the middle half received between $47 and $551.

Show as a table
Year Leigh O'Malley Internal Medicine median Middle half National median
2019 $1,862 $159 $48–$570 $163
2020 $321 $119 $33–$402 $114
2021 $227 $135 $37–$521 $132
2022 $1,032 $141 $42–$496 $149
2023 $1,417 $149 $45–$519 $160
2024 $695 $154 $47–$537 $164
2025 $467 $156 $47–$551 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Novo Nordisk Inc $822 56 payments
  2. Amgen Inc. $645 39 payments
  3. Pfizer Inc. $471 29 payments
  4. AstraZeneca Pharmaceuticals LP $451 30 payments
  5. AbbVie, Inc. $441 25 payments
  6. Lilly USA, LLC $375 23 payments
  7. GlaxoSmithKline, LLC. $358 22 payments
  8. Salix Pharmaceuticals, a division of Bausch Health US, LLC $319 18 payments
  9. Boehringer Ingelheim Pharmaceuticals, Inc. $314 25 payments
  10. Merck Sharp & Dohme Corporation $288 22 payments
  11. Other $1,537 94 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $5,973 377 payments
  2. Education $48 6 payments
Products named General payments · program years 2019–2025
  1. Ozempic $496 35 payments
  2. RYBELSUS $384 24 payments
  3. TRELEGY ELLIPTA $322 20 payments
  4. XIFAXAN $319 18 payments
  5. Repatha $290 19 payments
  6. EVENITY $282 16 payments
  7. AIMOVIG $253 16 payments
  8. Prolia $229 13 payments
  9. MOUNJARO $215 11 payments
  10. FARXIGA $205 14 payments
  11. Other $5,843 390 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 153 drugs

Part D claims

10,948

Median for Internal Medicine: 777

Drug cost

$1,013,339

Median for Internal Medicine: $73,373

Branded share of claims

20.5%

Median for Internal Medicine: 19.3%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Eliquis Apixaban Brand 214 $212,459
Ozempic Semaglutide Brand 129 $160,412
Jardiance Empagliflozin Brand 129 $150,702
Rybelsus Semaglutide Brand 31 $81,986
Trelegy Ellipta Fluticasone/Umeclidin/Vilanter Brand 43 $51,678
Xarelto Rivaroxaban Brand 42 $43,664
Januvia Sitagliptin Phosphate Brand 37 $32,655
Mounjaro Tirzepatide Brand 22 $29,870
Myrbetriq Mirabegron Brand 29 $23,531
Toujeo Max Solostar Insulin Glargine,hum.Rec.Anlog Brand 24 $15,369

The 10 drugs with the highest cost, of 153 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 104,182 Part D prescribers listed as Internal Medicine; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 17 billing codes

Paid by Medicare

$84,592

Medicare's payments for the services billed

Medicare patients

365

Average age 75

Services billed

1,183

248 women, 117 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 73%
Arthritis 36%
Diabetes 27%
Chronic kidney disease 20%
Depression 20%
Ischemic heart disease 19%
Osteoporosis 18%
Atrial fibrillation 15%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 23 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
NUZYRA
  • Paratek Pharmaceuticals, Inc. $46
$46 — —
Wegovy
  • Novo Nordisk Inc $42
$42 — —
FARXIGA
  • AstraZeneca Pharmaceuticals LP $41
$41 — —
AIRSUPRA
  • AstraZeneca Pharmaceuticals LP $39
$39 — —
MOUNJARO
  • Lilly USA, LLC $39
$39 22 —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 23 in the dashboard with a free account

Records

383 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Internal Medicine in North Carolina

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record